|
BG112910A
|
|
Oral drug composition with plant alkaloid for treatment of addictions
|
|
BG112738A
|
|
Method for preparation of purified galantamine hydrobromide
|
|
BG110504A
|
|
A compound containing inositolhexaphosphorous acid or its salts, and the method of its derivation
|
|
BG110141A
|
|
Galanthamine derivatives, methods for their obtaining and use
|
|
BG109765A
|
|
Medicinal form of a combined preparation and method of obtaining it
|
|
BG109422A
|
|
Concentrated hemodialysis solutions
|
|
BG109099A
|
|
Method for silybinin preparation
|
|
BG108969A
|
|
Medicamentous form of sildenafil
|
|
BG108784A
|
|
Drug formulation of propafenone and method of obtaining it
|
|
BG108686A
|
|
Cytisine-containing medicamentous form
|
|
BG108641A
|
|
Method for silimarin isolation from the fruits of silybum marianum (l) gaerth
|
|
BG108390A
|
|
Drug formulation and method of obtaining it
|
|
BG108355A
|
|
Galantamin-based combined medicamentous product
|
|
BG107927A
|
|
Medicamentous form of combined preparation and method for the production thereof
|
|
BG107499A
|
|
Standardized mixture of steroid saponins, method for the preparation and apllication thereof
|
|
BG106909A
|
|
Medicamentous form of silimarin and method for its preparation
|
|
BG106703A
|
|
Means for psoriasis treatment
|
|
BG106570A
|
|
Medicinal formulation of acenocoumarol and method of obtaining it
|
|
BG106571A
|
|
Medicamentous form of mesalazine and method for the preparation thereof
|
|
BG106174A
|
|
Method for the production of highly purified monocomponent insulin
|
